Quick Answer
FENNEC PHARMACEUTICALS INC. reported Total Revenue of $44.64 million for fiscal year 2025.
FENNEC PHARMACEUTICALS INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $44.64M -6.1% |
$47.54M +123.7% |
$21.25M +1284.5% |
$1.53M | — | $170.0K |
| Net Income | -$9.74M -2134.2% |
-$436.0K +97.3% |
-$16.05M +32.3% |
-$23.71M -36.7% |
-$17.35M +4.2% |
-$18.11M -41.8% |
| Diluted EPS | -$0.34 -1600.0% |
-$0.02 +96.7% |
-$0.60 +33.3% |
-$0.90 -34.3% |
-$0.67 +11.8% |
-$0.76 |
| Total Assets | $70.55M +57.0% |
$44.95M +125.0% |
$19.98M -25.8% |
$26.94M +20.2% |
$22.41M -28.7% |
$31.42M +122.1% |
| Cash and Equivalents | $36.79M +38.1% |
$26.63M +100.7% |
$13.27M -44.2% |
$23.77M +12.7% |
$21.10M -30.5% |
$30.34M +122.3% |
| Stockholders Equity | $35.47M +704.1% |
-$5.87M -161.3% |
$9.58M +472.9% |
-$2.57M -116.3% |
$15.77M -45.7% |
$29.07M +144.8% |
| R&D Expense | $250.0K -18.6% |
$307.0K +448.2% |
$56.0K -98.4% |
$3.53M -29.1% |
$4.98M -2.4% |
$5.11M -9.0% |
| Operating Income | -$6.28M -344.6% |
$2.57M +120.1% |
-$12.77M +43.5% |
-$22.59M -31.2% |
-$17.22M +3.7% |
-$17.89M -37.5% |
| Gross Profit | — | — | $19.99M +1279.8% |
$1.45M | — | — |
| Shares Outstanding | 34.16M +24.1% |
27.53M +1.9% |
27.03M +2.5% |
26.36M +1.3% |
26.01M +0.0% |
26.00M +30.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $12.46M | +78.7% | +29.1% |
| Net Income | September 30, 2025 | -$638.0K | +88.9% | +79.8% |
| Diluted EPS | September 30, 2025 | -$0.02 | +90.5% | +81.8% |
| Total Assets | September 30, 2025 | $49.26M | -16.4% | +9.8% |
| Cash and Equivalents | September 30, 2025 | $21.95M | -45.6% | +17.3% |
| Long-Term Debt | September 30, 2022 | $25.00M | — | +525.0% |
| Stockholders Equity | September 30, 2025 | -$4.49M | +13.1% | +39.8% |
| R&D Expense | September 30, 2025 | $29.0K | -70.1% | -72.9% |
| Operating Income | September 30, 2025 | -$189.0K | +96.4% | +93.1% |
| Gross Profit | September 30, 2023 | $6.18M | — | +94.6% |
| Shares Outstanding | September 30, 2025 | 28.06M | +2.3% | +1.2% |
- FENNEC PHARMACEUTICALS INC. reported Total Revenue of $44.64 million for fiscal year 2025.
- FENNEC PHARMACEUTICALS INC. showed a decrease of -6.1% in Total Revenue compared to the prior fiscal year.
- FENNEC PHARMACEUTICALS INC. reported Net Income of -$9.74 million for fiscal year 2025.
- FENNEC PHARMACEUTICALS INC. showed a decrease of -2134.2% in Net Income compared to the prior fiscal year.
- FENNEC PHARMACEUTICALS INC. reported Diluted EPS of $0.34 per share (loss) for fiscal year 2025.
- FENNEC PHARMACEUTICALS INC. showed a decrease of -1600.0% in Diluted EPS compared to the prior fiscal year.
- FENNEC PHARMACEUTICALS INC. reported Total Assets of $70.55 million for fiscal year 2025.
- FENNEC PHARMACEUTICALS INC. showed an increase of +57.0% in Total Assets compared to the prior fiscal year.
- FENNEC PHARMACEUTICALS INC. reported Cash and Equivalents of $36.79 million for fiscal year 2025.
- FENNEC PHARMACEUTICALS INC. showed an increase of +38.1% in Cash and Equivalents compared to the prior fiscal year.
- FENNEC PHARMACEUTICALS INC. reported Stockholders Equity of $35.47 million for fiscal year 2025.
- FENNEC PHARMACEUTICALS INC. showed an increase of +704.1% in Stockholders Equity compared to the prior fiscal year.
- FENNEC PHARMACEUTICALS INC. reported R&D Expense of $250.0 thousand for fiscal year 2025.
- FENNEC PHARMACEUTICALS INC. showed a decrease of -18.6% in R&D Expense compared to the prior fiscal year.
- FENNEC PHARMACEUTICALS INC. reported Operating Income of -$6.28 million for fiscal year 2025.
- FENNEC PHARMACEUTICALS INC. showed a decrease of -344.6% in Operating Income compared to the prior fiscal year.
- FENNEC PHARMACEUTICALS INC. reported Gross Profit of $19.99 million for fiscal year 2023.
- FENNEC PHARMACEUTICALS INC. showed an increase of +1279.8% in Gross Profit compared to the prior fiscal year.
- FENNEC PHARMACEUTICALS INC. reported Shares Outstanding of 34.16 million shares for fiscal year 2025.
- FENNEC PHARMACEUTICALS INC. showed an increase of +24.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: